Spotfire, Inc. has announced DecisionSite® for Microarray Analysis (DSMA), which gives drug makers a competitive advantage in quickly and accurately identifying potential drug targets. DSMA, available ...
On September 9, 2025, Altesa BioSciences announced a partnership with bioMérieux to use the BIOFIRE SPOTFIRE respiratory diagnostic platform as the primary point-of-care tool in its upcoming Phase 2B ...
PerkinElmer and Tibco Software inked a strategic alliance through which PerkinElmer has exclusively licensed Tibco’s Spotfire® analytics and data discovery platform for specific scientific R&D markets ...
Over 25,000 users in close to 1,000 organizations around the world use Spotfire DecisionSite to drive confident decision-making by quickly and easily spotting trends, outliers and unanticipated ...
In clinical, application authors in Spotfire regularly use SAS to extract data and prepare it and then do an initial analysis of that data in SAS. Now with Spotfire 4.5, those same clinicians can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results